TCGA study of liver cancer reveals potential targets for therapy

Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist.

http://ift.tt/2s5fNms